Cart
sales@molnova.com
Kojic acid
CAS No. 501-30-4
Kojic acid( —— )
Catalog No. M20588 CAS No. 501-30-4
Kojic acid is a fungal metabolite that inhibits tyrosinase an enzyme involved in melanin synthesis with an IC50 value of 30.6 μM for mushroom tyrosinase.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 41 | In Stock |
|
| 100MG | 37 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKojic acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionKojic acid is a fungal metabolite that inhibits tyrosinase an enzyme involved in melanin synthesis with an IC50 value of 30.6 μM for mushroom tyrosinase.
-
DescriptionKojic acid is a fungal metabolite that inhibits tyrosinase an enzyme involved in melanin synthesis with an IC50 value of 30.6 μM for mushroom tyrosinase.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number501-30-4
-
Formula Weight142.11
-
Molecular FormulaC6H6O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:28 mg/mL (197.03 mM)
-
SMILESOCc1cc(=O)c(O)co1
-
Chemical Name5-Hydroxy-2-(hydroxymethyl)-4H-pyran-4-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Rodrigues A P D Farias L H S Carvalho Antonio Sérgio C et al. A Novel Function for Kojic Acid a Secondary Metabolite from Aspergillus Fungi as Antileishmanial Agent[J]. PLoS ONE 2014 9(3):e91259-.
molnova catalog
related products
-
Acid Red 73
Acid red 73 is a red dye.
-
EED226
EED226 is a potent, selective, and orally bioavailable embryonic ectoderm development (EED) inhibitor with an IC50 of 22 nM.
-
Examorelin
Examorelin is an agonist of growth hormone-releasing factor (GHRF), and for the treatment of cardiac diseases.hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment.?
